199 related articles for article (PubMed ID: 11886250)
1. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy.
Torresi J; Earnest-Silveira L; Deliyannis G; Edgtton K; Zhuang H; Locarnini SA; Fyfe J; Sozzi T; Jackson DC
Virology; 2002 Feb; 293(2):305-13. PubMed ID: 11886250
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
Wakil SM; Kazim SN; Khan LA; Raisuddin S; Parvez MK; Guptan RC; Thakur V; Hasnain SE; Sarin SK
J Med Virol; 2002 Nov; 68(3):311-8. PubMed ID: 12226816
[TBL] [Abstract][Full Text] [Related]
3. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene.
Torresi J; Earnest-Silveira L; Civitico G; Walters TE; Lewin SR; Fyfe J; Locarnini SA; Manns M; Trautwein C; Bock TC
Virology; 2002 Jul; 299(1):88-99. PubMed ID: 12167344
[TBL] [Abstract][Full Text] [Related]
4. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus.
Torresi J
J Clin Virol; 2002 Aug; 25(2):97-106. PubMed ID: 12367644
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine.
Santos EA; Sucupira MV; Arabe J; Gomes SA
BMC Infect Dis; 2004 Aug; 4():29. PubMed ID: 15339340
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the reactivity pattern of murine monoclonal antibodies against wild-type hepatitis B surface antigen to G145R and other naturally occurring "a" loop escape mutations.
Cooreman MP; van Roosmalen MH; te Morsche R; Sünnen CM; de Ven EM; Jansen JB; Tytgat GN; de Wit PL; Paulij WP
Hepatology; 1999 Nov; 30(5):1287-92. PubMed ID: 10534351
[TBL] [Abstract][Full Text] [Related]
7. Failure of the lamivudine-resistant rtM204I hepatitis B virus mutants to efficiently support hepatitis delta virus secretion.
Vietheer PT; Netter HJ; Sozzi T; Bartholomeusz A
J Virol; 2005 May; 79(10):6570-3. PubMed ID: 15858045
[TBL] [Abstract][Full Text] [Related]
8. Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients.
Pollicino T; Isgrò G; Di Stefano R; Ferraro D; Maimone S; Brancatelli S; Squadrito G; Di Marco V; Craxì A; Raimondo G
Antivir Ther; 2009; 14(5):649-54. PubMed ID: 19704167
[TBL] [Abstract][Full Text] [Related]
9. Antiviral resistance mutations potentiate hepatitis B virus immune evasion through disruption of its surface antigen a determinant.
Sloan RD; Ijaz S; Moore PL; Harrison TJ; Teo CG; Tedder RS
Antivir Ther; 2008; 13(3):439-47. PubMed ID: 18572757
[TBL] [Abstract][Full Text] [Related]
10. Identification of rare polymerase variants of hepatitis B virus using a two-stage PCR with peptide nucleic acid clamping.
Ohishi W; Shirakawa H; Kawakami Y; Kimura S; Kamiyasu M; Tazuma S; Nakanishi T; Chayama K
J Med Virol; 2004 Apr; 72(4):558-65. PubMed ID: 14981758
[TBL] [Abstract][Full Text] [Related]
11. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
[TBL] [Abstract][Full Text] [Related]
12. Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance.
Hsu CW; Yeh CT; Chang ML; Liaw YF
Gastroenterology; 2007 Feb; 132(2):543-50. PubMed ID: 17258721
[TBL] [Abstract][Full Text] [Related]
13. Genotypic resistance to lamivudine among hepatitis B virus isolates in Mexico.
Alvarado-Esquivel C; de la Ascensión Carrera-Gracia M; Conde-González CJ; Juárez-Figueroa L; Ruiz-Maya L; Aguilar-Benavides S; Torres-Valenzuela A; Sablon E
J Antimicrob Chemother; 2006 Feb; 57(2):221-3. PubMed ID: 16373428
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of a quantitative HBV-DNA PCR assay in lamivudine treated hepatitis B-infected patients].
Deal C; Ajana F; Canva V; Mouton Y; Yazdanpanah Y; Wattré P; Bocket L
Ann Biol Clin (Paris); 2002; 60(5):581-8. PubMed ID: 12368144
[TBL] [Abstract][Full Text] [Related]
15. Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B.
Lo CM; Liu CL; Chan SC; Lau GK; Fan ST
J Hepatol; 2005 Aug; 43(2):283-7. PubMed ID: 15964658
[TBL] [Abstract][Full Text] [Related]
16. The genetic backbone modulates the phenotype of hepatitis B surface antigen mutants.
Beale MA; Ijaz S; Tedder RS
J Gen Virol; 2010 Jan; 91(Pt 1):68-73. PubMed ID: 19759242
[TBL] [Abstract][Full Text] [Related]
17. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
Quiros-Roldan E; Calabresi A; Lapadula G; Tirelli V; Costarelli S; Cologni G; Zaltron S; Puoti M; Carosi G; Torti C
Antivir Ther; 2008; 13(3):341-8. PubMed ID: 18572746
[TBL] [Abstract][Full Text] [Related]
18. Reverse transcriptase activity of hepatitis B virus (HBV) DNA polymerase within core capsid: interaction with deoxynucleoside triphosphates and anti-HBV L-deoxynucleoside analog triphosphates.
Lam W; Li Y; Liou JY; Dutschman GE; Cheng YC
Mol Pharmacol; 2004 Feb; 65(2):400-6. PubMed ID: 14742682
[TBL] [Abstract][Full Text] [Related]
19. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
[TBL] [Abstract][Full Text] [Related]
20. Coexistence of hepatitis B surface antigen (HBsAg) and heterologous subtype-specific antibodies to HBsAg among patients with chronic hepatitis B virus infection.
Zhang JM; Xu Y; Wang XY; Yin YK; Wu XH; Weng XH; Lu M
Clin Infect Dis; 2007 May; 44(9):1161-9. PubMed ID: 17407033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
